Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/-s0aMlSb4Xc   Oriahnn, a estrogen-progestin combo pharmaceutical, may now be prescribed for management of excessive menstrual bleed caused by fibroids of the uterus.  The two clinical trials of this oral medication revealed that the drug reduced bleeding between 7 and 8 fold.  This drug provides a non-surgical alternative to removal of the uterus for those women who may not desire or qualify to have the operation.  The chief, serious complications of Oriahnn use include a reduction in bone density and an increased risk of fractures and an increased risk of excessive blood clotting with heart attack or stroke.  Women with known osteoporosis, a smoking habit, or high blood pressure should consider other avenues of therapy.  This drug will not prevent pregnancy, and non-hormonal contraception should be employed.   https://www.fda.gov/news-events/press-announcements/fda-approves-new-option-treat-heavy-menstrual-bleeding-associated-fibroids-women   #approval #fda #oriahnn #fibroids #m